MarketCap
Facebook
X
Telegram
Ovid Therapeutics Interest Expense | OVID
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Ovid Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25 M | 35.5 M | 6.94 M | 1.38 M | -45.7 K | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 35.5 M | -45.7 K | 13.8 M |
Quarterly Interest Expense Ovid Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.58 M | 689 K | 858 K | 22 M | 365 K | 389 K | 2.32 M | 1.47 M | -780 K | 29 M | 5.72 M | 2.87 M | 776 K | 1.76 M | 1.54 M | - | 836 K | -284 K | 209 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 29 M | -780 K | 3.96 M |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Annexon
ANNX
|
57 K | $ 4.2 | -0.36 % | $ 651 M |  USA |
 |
AbbVie
ABBV
|
2.89 B | $ 294.72 | 0.32 % | $ 521 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
741 K | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Avenue Therapeutics
ATXI
|
294 K | - | -52.27 % | $ 4.45 M | USA |
 |
Achieve Life Sciences
ACHV
|
-36 K | $ 6.78 | 0.89 % | $ 296 M | USA |
 |
Axon Enterprise
AXON
|
99.9 M | $ 316.97 | 4.77 % | $ 24.7 B | USA |
 |
TFF Pharmaceuticals
TFFP
|
14.5 K | - | -60.05 % | $ 125 K | USA |
 |
Bristol-Myers Squibb Company
BMY
|
-674 M | $ 62.89 | 0.18 % | $ 128 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-1.73 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Axcella Health
AXLA
|
3.02 M | - | -16.42 % | $ 249 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
45.6 M | $ 58.59 | 4.29 % | $ 7.04 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
293 K | - | - | $ 2.02 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
5.2 M | $ 159.75 | 5.35 % | $ 20.9 B | USA |
 |
Orgenesis
ORGS
|
-4.51 M | - | -33.86 % | $ 61.2 M | USA |
 |
Codiak BioSciences
CDAK
|
2.7 M | - | -55.98 % | $ 2.15 M | USA |
 |
Jazz Pharmaceuticals plc
JAZZ
|
1.44 M | $ 248.31 | 1.17 % | $ 15.1 B |  Irlanda |
 |
Johnson & Johnson
JNJ
|
7.21 B | $ 280.31 | -0.17 % | $ 675 B | USA |
 |
Kala Pharmaceuticals
KALA
|
5.15 M | $ 0.17 | 0.64 % | $ 1.39 M | USA |
 |
BioLineRx Ltd.
BLRX
|
1.25 M | $ 1.49 | -1.97 % | $ 3.67 B | Israel |
 |
Sage Therapeutics
SAGE
|
29 K | - | - | $ 527 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
561 K | $ 1.59 | -2.76 % | $ 2.62 M | Israel |
 |
Lineage Cell Therapeutics
LCTX
|
-132 K | $ 1.13 | 8.17 % | $ 260 M | USA |
 |
Paratek Pharmaceuticals
PRTK
|
18.1 M | - | - | $ 121 M | USA |
 |
Eli Lilly and Company
LLY
|
-25.4 M | $ 1 437.4 | 0.36 % | $ 1.29 T | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
442 K | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Compugen Ltd.
CGEN
|
281 K | $ 2.09 | -0.24 % | $ 195 M | Israel |
 |
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-357 K | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
GeoVax Labs
GOVX
|
1.29 K | $ 2.13 | -20.4 % | $ 2.04 M | USA |
 |
Unity Biotechnology
UBX
|
2.45 M | - | -33.41 % | $ 3.37 M | USA |
 |
MediciNova
MNOV
|
-12.8 K | $ 1.41 | 0.36 % | $ 69.2 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
1.6 M | - | - | $ 521 M | USA |
 |
Seelos Therapeutics
SEEL
|
75 K | - | -47.76 % | $ 6.27 M | USA |
 |
Celldex Therapeutics
CLDX
|
927 K | $ 30.18 | -1.53 % | $ 2 B | USA |
 |
Moderna
MRNA
|
-8 M | $ 248.62 | -0.88 % | $ 96.7 B | USA |
 |
Kiromic BioPharma
KRBP
|
599 K | - | 6.61 % | $ 3.08 M | USA |
 |
Nektar Therapeutics
NKTR
|
361 K | $ 38.41 | 1.67 % | $ 648 M | USA |
|
Applied Molecular Transport
AMTI
|
-4 K | - | - | $ 10.1 M | USA |
 |
CorMedix
CRMD
|
1.4 M | $ 5.31 | -2.23 % | $ 383 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
86.6 M | $ 45.39 | 0.53 % | $ 4.08 B |  Schweiz |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
28 K | $ 1.66 | -2.64 % | $ 1.12 B | Israel |
 |
Deciphera Pharmaceuticals
DCPH
|
16.4 M | - | - | $ 2.18 B | USA |
 |
Idera Pharmaceuticals
IDRA
|
7 K | - | -23.04 % | $ 26.6 M | USA |
 |
Tyme Technologies
TYME
|
70.2 K | - | 8.07 % | $ 54 M | USA |
 |
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | USA |
 |
Verona Pharma plc
VRNA
|
340 K | - | - | $ 69.7 B | Britain |